BPC-157 Muscle Recovery: Dose Comparison
Grade 1 muscle strain 200–300mcg daily subQ 3–5 days (inflammation reduction) 10–14 days (fiber continuity restored) Return to pain-free range of motion Peptide accelerates inflammation resolution but doesn't bypass the myofiber regeneration timeline. Expect f
This comparison does not assign a generated winner or score.
- Grade 1 muscle strain
- 200–300mcg daily subQ
- 3–5 days (inflammation reduction)
- 10–14 days (fiber continuity restored)
- Return to pain-free range of motion
- Peptide accelerates inflammation resolution but doesn't bypass the myofiber regeneration timeline. Expect functional improvement by week 2, not week 1
- Grade 2 muscle tear
- 300–500mcg daily subQ
- 5–7 days (reduced swelling and pain)
- 14–21 days (partial tensile strength recovery)
- Load tolerance at 70–80% baseline
- Angiogenesis and collagen deposition are measurable by day 14 but full remodeling requires 4–6 weeks. Peptide reduces scar tissue formation, which matters for re-injury risk
- Tendon strain (partial tear)
- 250–400mcg daily subQ
- 7–10 days (reduced pain on loading)
- 21–28 days (measurable strength improvement)
- Biomechanical tensile strength testing
- BPC-157 shows the strongest evidence base for tendon repair. Upregulation of Type I collagen and reduced fibrosis translate to better long-term outcomes than muscle injuries
- Ligament sprain (Grade 2)
- 5–7 days (reduced joint instability sensation)
- 28–42 days (restored mechanical stability)
- Joint laxity measurement under stress
- Symptom relief appears faster than structural healing. The peptide's anti-inflammatory effect reduces pain before ligament architecture is fully restored
- Chronic tendinopathy
- 10–14 days (reduced pain during activity)
- 4–8 weeks (collagen remodeling and reduced calcification)
- Ultrasound imaging of tissue structure
- Chronic injuries require longer protocols. The peptide's effect on fibroblast activity and neovascularization becomes measurable only after sustained daily administration